- Home
- DAVA vs KZIA Comparison
DAVA vs KZIA Comparison
Compare DAVA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | KZIA |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United Kingdom | Australia |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.2M | 186.7M |
| IPO Year | 2015 | 2002 |
Fundamental Metrics
Financial Performance| Metric | DAVA | KZIA |
|---|---|---|
| Price | $2.05 | $8.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $5.35 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 761.1K | 251.2K |
| Earning Date | 11-02-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.12 | N/A |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $4.86 |
| 52 Week High | $9.88 | $17.40 |
Technical Indicators
Market Signals| Indicator | DAVA | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 27.25 |
| Support Level | $1.60 | $5.15 |
| Resistance Level | $3.11 | $8.18 |
| Average True Range (ATR) | 0.13 | 0.58 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 97.73 | 3.54 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.